亚低温治疗高温高湿环境下重型颅脑损伤的临床护理

目的 探讨亚低温治疗高温高湿环境下重型颅脑损伤的护理方法。方法 高温高湿环境下的重型颅脑损伤患者60例，随机分为亚低温治疗组和对照组。规范护理程序，严密观察病人生命体征变化，采取积极护理措施，减少并发症。结果 亚低温治疗24h后颅内压逐渐下降，脑组织PO2逐渐上升，伤后3个月亚低温治疗组的良好率明显高于对照组（P〈0.05），而死亡率明显低于对照组（P〈0．01）。结论 精心护理有助于改善亚低温治疗的高温高湿环境下重型颅脑损伤病人的预后。     

瑞波西汀与多虑平治疗老年抑郁症对照研究

目的观察瑞波西汀治疗老年抑郁症的疗效和安全性。方法随机将60例年龄≥60岁的老年抑郁症患者分为多虑平组（30例）和瑞波西汀组（30例），疗程6周，采用汉密尔顿抑郁量表（HAMD）和副反应量表（TESS）在治疗前和治疗后1、2、4、6周末评定药物疗效和副反应。结果两组疗效无显著差异，HAMD总分反各因子分从疗后2周至6周均较治疗前显著降低，两组间比较无显著性差异；治疗结束时TESS评分瑞波西汀组显著低于多虑平组。结论瑞波西汀适合于老年抑郁症患者的治疗，服用方便、安全，可首选使用。     

不明原因复发性流产患者子宫内膜/早孕蜕膜组织HOXA-1O基因的表达

目的探讨不明原因复发性流产（URSA）与子宫内膜／早孕蜕膜组织HOXA-10基因表达的关系。方法采用原位杂交技术，以HOXA-10反义核苷酸为探针检测51例URSA患者及38例正常生育（NF）组的分泌期子宫内膜／早孕蜕膜组织HOXA-10mRNA的表达水平，并以灰度阳性单位（PU值）表示。结果NF组子宫内膜分泌早期HOXA-10mRNA表达的PU值腺体为（6．66±0．11），间质为（6．76±0．15）；分泌中期分别为（10．95±0．90）及（11．46±1．08）；分泌晚期分别为（11．05±1．12）及（11．54±1．10）；蜕膜组织分别为（11．55±1．14）及（11．93±1．92）；分泌中晚期及蜕膜组织的Pu值显著高于分泌早期。URSA组不同时期子宫内膜及早孕蜕膜组织中HOXA-10mRNA的表达水平基本一致，无明显的分泌中晚期及早孕期峰，并且分泌中晚期及早孕蜕膜组织的PU值明显低于NF同期组。两组各期腺体和间质的PU值无显著差异。结论子宫内膜HOXA-10基因在分泌中晚期及早孕蜕膜组织中的高表达可能和孕卵着床及妊娠维持密切相关，其表达缺陷可能是导致URSA发生的重要原因之一。     

理疗床和手法治疗肩关节周围炎的随机对照临床观察

目的评价两种不同方法治疗肩关节周围炎的临床疗效.方法采用随机数字表将患者随机分为治疗组和对照组.治疗组36例,男8例,女28例,年龄45～64岁;对照组36例,男15例,女21例,年龄45～62岁.治疗组采用温热理疗床治疗4周.对照组采用推拿按摩手法治疗4周.分别在筛选期(治疗前)及治疗后14、28 d(治疗结束时)各观察记录1次,对比两组肩部疼痛症状、肩关节功能及症状疗效的改善.结果两组治疗前后各观察指标比较,肩部疼痛症状明显改善(P＜0.05);肩关节上举外展、外旋、后伸内旋活动角度均有明显增大(P＜0.05).治疗结果显示治疗组显效4例,有效25例,无效7例;对照组痊愈12例,显效13例,有效7例,无效4例.两组疗效比较差异有统计学意义(P＜0.05),对照组优于治疗组.结论理疗床和手法对肩关节周围炎引起的一系列临床症状及功能障碍均具有一定程度的改善效果.     

The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy.

BACKGROUND AND PURPOSE: The potential risk of prolongation of treatment time in cervical cancer has been reported for many low-dose rate (LDR) studies, with an estimated loss of local control ranging from 0.3 to 1.6% per day of treatment prolongation. Since the treatment schedule for fractionated high-dose rate intracavitary brachytherapy (HDRICB) is not directly comparable with that for low-dose rate studies, this report aims to evaluate the adverse effect of treatment prolongation specifically for cervical cancer treated with HDRICB. MATERIAL AND METHODS: From September 1992 to December 1997, 257 patients diagnosed with uterine cervical cancer (35 Ib, 26 IIa, 122 IIb, 10 IIIa, 57 IIIb, 7 IVa), who underwent external radiotherapy combined with between two and four courses of HDRICB and a minimum of 3 years of follow-up (median 57 months), were analyzed. Treatment consisted of irradiation of the whole pelvis with 44-45 Gy consisting of 22-25 fractions by 5 weeks, with the dose boosted to 54-58 Gy (with central shielding) for patients diagnosed as FIGO stage IIb-IVa bilateral parametrial disease. HDRICB was performed using an Ir-192 remote afterloading technique at 1-week intervals. The standard prescribed dose for each course of HDRICB was 7.2 Gy to point A for three insertions (before July 1995), or 6.0 Gy to point A for four insertions (after July 1995). Total prescribed point A doses (external beam radiotherapy+HDRICB) ranged from 58 to 71.6 Gy (median, 65.6 Gy) for stage IB-IIA, while analogous dosage for larger lesions (stage IIb-IVa) ranged from 59 to 75.6 Gy (median, 65.6 Gy). Kaplan-Meier and multivariate analyses were used to test the effect of treatment time on pelvic control rate (PCR) and cause-specific survival (CSS) at 5 years. RESULTS: Median treatment time was 63 days. For all stages of disease, the 5-year CSS and PCR were significantly different comparing treatment times of less than and greater than or equal to 63 days [83% and 65% (P=0.004], 93% and 83% (P=0.02), respectively]. These associations were also significant for stage Ib/IIa [97% and 79% (P=0.01), and 100% and 87% (P=0.02), respectively), but not for stage IIb [75% and 72% (P=0.79), and 93% and 87% (P=0.83), respectively] or stage III [66% and 49% (P=0.2), and 83% and 72% (P=0.21), respectively]. Multivariate analysis identified three prognostic factors for CSS, stage (P<0.001), tumor response to external RT (P=0.001), and overall treatment time (OTT; P=0.006). Prognostic factors for pelvic failure were stage (P<0.001), tumor response to external RT (P=0.001), and OTT (P=0.03). Prolongation of treatment time resulted in a daily decrease in pelvic control rate of 0.67% overall, and 0.43% for stage Ib-IIa, 0.57% for stage IIb, and 0.73% for stage III patients. CONCLUSION: Analysis of the data from the current study demonstrates that the adverse effect of treatment prolongation was observed later in the treatment course for the high-dose rate (HDR) series compared to the LDR analog, however, treatment-time prolongation still negatively influenced the cause-specific survival and pelvic control rate for both dosage groups.     

广东省信宜市蚊媒种类密度初步调查

目的 调查广东省信宜市怀乡镇和水口镇蚊媒数量及种类分布。方法 怀乡镇检查猪场、猪栏和牛房中蚊媒的分布；水口镇以牛诱和猪栏检查的方法调查蚊媒的分布。于19：00～21：30点观察蚊媒出现的情况，并以捕蚊管捕捉蚊媒。对所捕按蚊进行计数、分类。结果 共捕获蚊媒602只，其中包含5个种：骚扰阿蚊、三带喙库蚊、中华按蚊、多斑按蚊和嵌斑按蚊。三带喙库蚊为当地的优势蚊种，其占除阿蚊外总蚊量的90．8％。结论 三带喙库蚊为信宜市的优势蚊种。     

扩髓交锁髓内钉治疗胫骨萎缩性骨不连

[目的] 探讨胫骨萎缩性骨不连的原因及扩髓交锁髓内钉治疗胫骨萎缩性骨不连的效果。[方法] 对26例胫骨萎缩性骨不连的病例采用扩大髓腔的交锁髓内钉内固定。[结果] 经6个月～2年的随访，骨折全部愈合，关节功能明显改善。[结论] 扩大 髓腔的交锁髓内钉内固定是治疗胫骨萎缩性骨不连的理想方法。     

高效液相色谱法测定峰丁麻滴眼剂中盐酸麻黄碱含量

目的　建立高效液相色谱法测定蜂丁麻滴眼剂中盐酸麻黄碱含量的方法。　方法　采用YWGC18分析色谱柱 ( 4 6mmID× 2 5 0mm ,粒径 10 μm) ,C18保护柱 ( 4 6mmID× 5mm ,粒径 10 μm) ,流动相 10 %乙腈 ( 0 5 %三乙胺 ,磷酸调pH3 0 ) ,流速 1 0ml/min ,检测波长 2 0 8nm ,测定对照品和样品色谱图 ,记录盐酸麻黄碱色谱峰面积 ,计算其含量。　结果　盐酸麻黄碱的理论板数为 10 0 0 0。回归方程 :y =90 5 878 16 15 1738x ,r=0 9999,线性范围 0 4 0 32～ 1 6 13μg。平均回收率为 99 2 % (RSD1 6 % )。　结论　该法操作简便 ,结果准确 ,可用于测定蜂丁麻滴眼剂中盐酸麻黄碱的含量     

PCR-SSCP法检测结核分枝杆菌耐药性

目的：探讨耐多药结核分枝杆菌耐药基因突变与耐药性的关系以及聚合酶链反应-单链构象多态性分析(poly merase chain reaction-single strand cinfomlation polymorphism，PCR-SSCP)方法的临床应用价值。方法：用PCR-SSCP方法检测58株结核分枝杆菌临床分离株katG，rpoB，rpsL基因突变并与常规药敏试验检测结果进行对比。结果：经常规药敏试验检测，58株结核分枝杆菌临床分离株中共有41株耐药，其中，耐异烟肼(INH)为35株，高耐药株27株；耐利福平(RFP)为31株，高耐药株24株；耐链霉素(SM)有31株，高耐药株26株。同时耐3种药物的有21株(51．2％)，耐2种药物的14株(34．1％)，单耐药株6株(14．6％)．PCR-SSCP方法对58株临床分离株katG，rpoB，rpsL基因突变的检测率为40％(23／58)，45％(26／58)，38％(22／58)，其中检出3个基因同时突变的有13株(32％)，2种基因突变的12株(29％)，1种基因突变的有10株(23．8％)．常规药敏试验与PCR-SSCP法检出结核分枝杆菌同时耐3种药物的符合率为61．9％(13／21)，检出耐2种药物的符合率为85．70k，(12／14)，检出耐1种药物的符合率为50％(3／6)．高耐药株中突变率为80．5％(62／77)，低耐药株中突变率为60％(12／20)．结论：PCR-SS-CP方法对耐2种以上药物的结核杆菌检出率较高，且耐药基因突变率随着耐药浓度增高而增高。将PCR-SSCP法与药敏试验联合应用可互相弥补，已成为临床指导用药的好方法。     

颅脑外伤性病变的CT检查及其临床意义

目的：探讨颅脑外伤严重程度及CT征象与预后的关系，并探讨CT复查的最佳时间及临床意义。方法：回顾性分析80例颅脑外伤的严重程度与初次CT征象的关系，统计分析复查CT发现新病变的数目、程度及时间。结果：颅脑外伤的严重程度与初次CT征象符合率为92．5％(74／80)。外伤后即刻昏迷、CT显示重度复合伤、脑干损伤或弥漫性脑白质损伤的病死率达70．0％(21／30)。1～3d复查CT发现迟发性病变80个，4—7d21个，7d后8个。结论：临床病情与CT征象变化对判断预后有重要意义，颅脑外伤后3、7d是复查CT的最佳时机，出现病情变化应随时复查。